LUMICKS

About:

LUMICKS provides single-molecule analysis technologies for cancer research and immunotherapy.

Website: https://lumicks.com

Twitter/X: LUMICKS_nl

Top Investors: European Investment Bank, T. Rowe Price, SoftBank Vision Fund, Lauxera Capital Partners, Irving Investors

Description:

LUMICKS delivers state-of-the-art technologies for the study of biology and cancer at the single-molecule and single-cell levels. It aims to build the unfinished bridge between structure and function at the molecular and cellular levels. Using its product C-Trap Optical Tweezers, Fluorescence Microscopy, scientists are able to analyze complex biological processes in real-time. Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.

Total Funding Amount:

97.9M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Amsterdam, Noord-Holland, The Netherlands

Founded Date:

2014-03-01

Contact Email:

info(AT)lumicks.com

Founders:

Andrea Candelli, Olivier Heyning

Number of Employees:

101-250

Last Funding Date:

2024-10-10

IPO Status:

Private

Industries:

© 2025 bioDAO.ai